It was a tough week for stocks. After eking out gains last week, the U.S. indexes gave up those gains and then some. There was some positive data on the U.S. economy, including lower-than-expected initial unemployment claims, better-than-expected manufacturing numbers from the Empire and Philadelphia Fed reports, and slowing consumer price inflation. However, concerns over Europe's ugly situation overwhelmed investors, and they fled stocks.
The Dow Jones Industrial Average
Top 3 Performing Sectors
Russell 3000 Sector
Weekly Price Change
Month-to-Date Price Change
Source: S&P Capital IQ. Weekly price change is Dec. 9-Dec. 16. Monthly price change is Nov. 30-Dec. 16.
One stock providing a boost to the health care group was ISTA Pharmaceuticals
Also getting a takeover boost on Friday was RSC Holdings
Top 3 Performing Russell 3000 Companies
Weekly Price Change
|Synovis Life Technologies||49%|
Source: S&P Capital IQ. Weekly price change is Dec. 9-Dec. 16.
Also among the week's top performers were Vertex Pharmaceuticals
Zoll shareholders, meanwhile, breathed a sigh of relief this week after Medicare opted to not make any adjustments to its reimbursements for the company's LifeVest product. Zoll shares tacked on 24% for the week.
That's it for this week's top-performers recap. If you're looking for some ideas for strong outperformers in the year ahead, The Motley Fool has created a brand new free report titled "The Motley Fool's Top Stock for 2012." In it, my fellow Fools reveal a top pick that's poised for explosive growth ahead. Get instant access -- it's free.
Motley Fool newsletter services have recommended buying shares of Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer has no financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter, @KoppTheFool, or on Facebook. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.